Biogen Inc
BIIB181.940USD
-0.020-0.01%
收盘 11/26, 16:00（美东）报价延迟15分钟
26.69B总市值
16.59市盈率 TTM
关于 Biogen Inc 公司
Biogen Inc. 是一家全球性生物制药公司。该公司致力于为全球患有严重和复杂疾病的人们发现、开发和提供先进的治疗方法。该公司经营一系列药物，用于治疗多发性硬化症 (MS)、脊髓性肌萎缩症 (SMA)、阿尔茨海默病和肌萎缩侧索硬化症 (ALS)。该公司专注于推进其在神经病学、专业免疫学和罕见疾病领域的产品线。其上市产品包括用于治疗 MS 的 TECFIDERA、VUMERITY、AVONEX、PLEGRIDY、TYSABRI 和 FAMPYRA；用于治疗 SMA 的 SPINRAZA；用于治疗弗里德赖希共济失调的 SKYCLARYS；用于治疗 ALS 的 QALSODY 和用于治疗严重斑块状银屑病的 FUMADERM。它还与 Eisai 合作，将 LEQEMBI 商业化，用于治疗阿尔茨海默病，并与 Sage 合作，将 ZURZUVAE 商业化，用于治疗产后抑郁症 (PPD)。
Biogen Inc简介
公司代码BIIB
公司名称Biogen Inc
上市日期Sep 17, 1991
CEOMr. Christopher A. (Chris) Viehbacher
员工数量7605
证券类型Ordinary Share
年结日Sep 17
公司地址225 Binney Street
城市CAMBRIDGE
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编02142
电话17814642000
网址https://www.biogen.com/
公司代码BIIB
上市日期Sep 17, 1991
CEOMr. Christopher A. (Chris) Viehbacher
Biogen Inc公司高管
名称
名称/职务
职务
持股
持股变动
Ms. Susan H. Alexander, Esq., J.D.
Ms. Susan H. Alexander, Esq., J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
56.35K
+55.38%
Ms. Caroline D. Dorsa
Ms. Caroline D. Dorsa
Independent Chairman of the Board
Independent Chairman of the Board
29.22K
+12.13%
Dr. Ginger Gregory, Ph.D.
Dr. Ginger Gregory, Ph.D.
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
17.50K
+28.86%
Ms. Nicole Murphy
Ms. Nicole Murphy
Executive Vice President - Pharmaceutical Operations and Technology
Executive Vice President - Pharmaceutical Operations and Technology
14.22K
+1.19%
Dr. Stephen A. Sherwin, M.D.
Dr. Stephen A. Sherwin, M.D.
Independent Director
Independent Director
12.35K
+23.75%
Mr. Rachid Izzar
Mr. Rachid Izzar
Executive Vice President, Head of Global Product Strategy and Commercialization
Executive Vice President, Head of Global Product Strategy and Commercialization
11.23K
-16.53%
Mr. Jesus B. Mantas
Mr. Jesus B. Mantas
Independent Director
Independent Director
8.42K
+39.19%
Ms. Priya Singhal, M.D.
Ms. Priya Singhal, M.D.
Executive Vice President, Head of Development
Executive Vice President, Head of Development
5.77K
-8.22%
Dr. Maria C. Freire, Ph.D.
Dr. Maria C. Freire, Ph.D.
Independent Director
Independent Director
5.47K
+76.33%
Ms. Susan Langer
Ms. Susan Langer
Independent Director
Independent Director
3.79K
+166.90%
查看更多
名称
名称/职务
职务
持股
持股变动
Ms. Susan H. Alexander, Esq., J.D.
Ms. Susan H. Alexander, Esq., J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
56.35K
+55.38%
Ms. Caroline D. Dorsa
Ms. Caroline D. Dorsa
Independent Chairman of the Board
Independent Chairman of the Board
29.22K
+12.13%
Dr. Ginger Gregory, Ph.D.
Dr. Ginger Gregory, Ph.D.
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
17.50K
+28.86%
Ms. Nicole Murphy
Ms. Nicole Murphy
Executive Vice President - Pharmaceutical Operations and Technology
Executive Vice President - Pharmaceutical Operations and Technology
14.22K
+1.19%
Dr. Stephen A. Sherwin, M.D.
Dr. Stephen A. Sherwin, M.D.
Independent Director
Independent Director
12.35K
+23.75%
Mr. Rachid Izzar
Mr. Rachid Izzar
Executive Vice President, Head of Global Product Strategy and Commercialization
Executive Vice President, Head of Global Product Strategy and Commercialization
11.23K
-16.53%
收入明细
单位: USD更新时间: 10月6日 周一
单位: USD更新时间: 10月6日 周一
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
业务USD
名称
营收
占比
MS product revenues-TYSABRI
839.80M
31.74%
Spinal Muscular Atrophy-SPINRAZA
543.00M
20.53%
MS product revenues-Fumarate
405.90M
15.34%
MS product revenues-Interferon
246.70M
9.33%
Biosimilar product revenues-BENEPALI
112.10M
4.24%
其他
498.00M
18.82%
地区USD
名称
营收
占比
United States
1.38B
52.21%
Rest of World
937.60M
35.44%
United states-Revenues from anti-CD20 therapeutic
467.30M
17.66%
Rest of World-Other revenues
244.60M
9.25%
业务
地区
业务USD
名称
营收
占比
MS product revenues-TYSABRI
839.80M
31.74%
Spinal Muscular Atrophy-SPINRAZA
543.00M
20.53%
MS product revenues-Fumarate
405.90M
15.34%
MS product revenues-Interferon
246.70M
9.33%
Biosimilar product revenues-BENEPALI
112.10M
4.24%
其他
498.00M
18.82%
股东统计
更新时间: 11月16日 周日
更新时间: 11月16日 周日
持股股东
股东类型
持股股东
持股股东
占比
The Vanguard Group, Inc.
11.73%
PRIMECAP Management Company
10.19%
BlackRock Institutional Trust Company, N.A.
5.60%
State Street Investment Management (US)
4.99%
Wellington Management Company, LLP
2.89%
其他
64.59%
持股股东
持股股东
占比
The Vanguard Group, Inc.
11.73%
PRIMECAP Management Company
10.19%
BlackRock Institutional Trust Company, N.A.
5.60%
State Street Investment Management (US)
4.99%
Wellington Management Company, LLP
2.89%
其他
64.59%
股东类型
持股股东
占比
Investment Advisor
52.44%
Investment Advisor/Hedge Fund
26.19%
Hedge Fund
8.03%
Pension Fund
2.94%
Research Firm
2.45%
Sovereign Wealth Fund
1.59%
Bank and Trust
1.59%
Individual Investor
0.17%
Family Office
0.15%
其他
4.45%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
2020
136.90M
93.32%
-6.47M
2025Q2
2075
135.74M
92.58%
-12.69M
2025Q1
2149
136.82M
93.38%
-11.44M
2024Q4
2130
138.58M
94.69%
-5.19M
2024Q3
2109
135.95M
93.33%
-6.54M
2024Q2
2116
135.72M
93.21%
-7.14M
2024Q1
2121
136.44M
93.87%
-5.95M
2023Q4
2151
135.61M
93.59%
-2.07M
2023Q3
2177
132.42M
91.43%
-7.53M
2023Q2
2240
133.77M
92.42%
-4.86M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
The Vanguard Group, Inc.
17.21M
11.74%
+255.44K
+1.51%
Jun 30, 2025
PRIMECAP Management Company
15.80M
10.78%
-141.14K
-0.89%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
8.19M
5.59%
-504.36K
-5.80%
Jun 30, 2025
State Street Investment Management (US)
7.47M
5.09%
+71.90K
+0.97%
Jun 30, 2025
Wellington Management Company, LLP
4.80M
3.27%
+125.98K
+2.70%
Jun 30, 2025
Geode Capital Management, L.L.C.
3.92M
2.67%
+71.29K
+1.85%
Jun 30, 2025
Point72 Asset Management, L.P.
3.83M
2.61%
+3.42M
+840.86%
Jun 30, 2025
Invesco Capital Management (QQQ Trust)
3.00M
2.05%
-10.62K
-0.35%
Aug 31, 2025
Norges Bank Investment Management (NBIM)
2.26M
1.54%
-61.02K
-2.62%
Jun 30, 2025
Invesco Capital Management LLC
2.04M
1.39%
+32.06K
+1.59%
Jun 30, 2025
查看更多
持股ETF
更新时间: 11月6日 周四
更新时间: 11月6日 周四
机构名称
占比
Invesco Biotechnology & Genome ETF
5.03%
iShares Neuroscience and Healthcare ETF
4.13%
First Trust NASDAQ Pharmaceuticals ETF
3.82%
VanEck Biotech ETF
3.33%
First Trust NYSE Arca Biotechnology Index Fund
3.24%
Invesco Pharmaceuticals ETF
2.74%
First Trust Health Care Alphadex Fund
2.36%
Global X US Cash Flow Kings 100 ETF
2.26%
ProShares Ultra Nasdaq Biotechnology
2.12%
Invesco Nasdaq Biotechnology ETF
2.08%
查看更多
Invesco Biotechnology & Genome ETF
占比5.03%
iShares Neuroscience and Healthcare ETF
占比4.13%
First Trust NASDAQ Pharmaceuticals ETF
占比3.82%
VanEck Biotech ETF
占比3.33%
First Trust NYSE Arca Biotechnology Index Fund
占比3.24%
Invesco Pharmaceuticals ETF
占比2.74%
First Trust Health Care Alphadex Fund
占比2.36%
Global X US Cash Flow Kings 100 ETF
占比2.26%
ProShares Ultra Nasdaq Biotechnology
占比2.12%
Invesco Nasdaq Biotechnology ETF
占比2.08%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
常见问题
Biogen Inc的前五大股东是谁？
Biogen Inc 的前五大股东如下：
The Vanguard Group, Inc.持有股份：17.21M，占总股份比例：11.74%。
PRIMECAP Management Company持有股份：15.80M，占总股份比例：10.78%。
BlackRock Institutional Trust Company, N.A.持有股份：8.19M，占总股份比例：5.59%。
State Street Investment Management (US)持有股份：7.47M，占总股份比例：5.09%。
Wellington Management Company, LLP持有股份：4.80M，占总股份比例：3.27%。
The Vanguard Group, Inc.持有股份：17.21M，占总股份比例：11.74%。
PRIMECAP Management Company持有股份：15.80M，占总股份比例：10.78%。
BlackRock Institutional Trust Company, N.A.持有股份：8.19M，占总股份比例：5.59%。
State Street Investment Management (US)持有股份：7.47M，占总股份比例：5.09%。
Wellington Management Company, LLP持有股份：4.80M，占总股份比例：3.27%。
Biogen Inc的前三大股东类型是什么？
Biogen Inc 的前三大股东类型分别是：
The Vanguard Group, Inc.
PRIMECAP Management Company
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
PRIMECAP Management Company
BlackRock Institutional Trust Company, N.A.
有多少机构持有Biogen Inc(BIIB)的股份？
截至2025Q3，共有2020家机构持有Biogen Inc的股份，合计持有的股份价值约为136.90M，占公司总股份的93.32%。与2025Q2相比，机构持股有所增加，增幅为0.73%。
哪个业务部门对Biogen Inc的收入贡献最大？
在FY2025Q2，MS product revenues-TYSABRI业务部门对Biogen Inc的收入贡献最大，创收839.80M，占总收入的31.74%。
